Expression and intracellular localization of matrix metalloproteinases in intraductal papillary mucinous neoplasms of the pancreas
- 151 Downloads
- 4 Citations
Abstract
To analyze the expression of matrix metalloproteinases (MMPs) and their relationships with the histological grades of the intraductal papillary mucinous neoplasm (IPMN) of the pancreas, we examined the frequency of expression and intracellular localization of MMP1, MMP2, MMP3, MMP7, and MMP9 in IPMN by immunohistochemistry. A total of 45 IPMN lesions (14 adenomas, 17 borderline lesions, nine noninvasive carcinomas, and five invasive lesions) from 21 patients were examined. MMP1, MMP2, MMP7, and MMP9 were expressed in tumor cells. Frequency of tumor cells expressing MMP7 was low in adenomas (median, 5.0%), higher in borderline lesions (median, 30.0%), in noninvasive carcinomas (median, 50.0%), and in invasive lesions (median, 80.0%), with a significant trend (P < 0.0001). Such a trend was also observed when the lesions were classified into gastric and intestinal subtypes (P < 0.0001 and P = 0.011, respectively). Basolateral expression of MMP7 in tumor cells was more prominent in lesions with higher histological grades (P < 0.0001). The frequency and the localization of MMP1, MMP2, and MMP9 did not correlate to the histological grades. MMP7 may contribute to the process by which IPMN advances from adenoma to carcinoma and to subsequent invasion of tumor cells in IPMN.
Keywords
Intraductal papillary mucinous neoplasm Matrix metalloproteinase ImmunohistochemistryNotes
Conflict of interest statement
We declare that we have no conflict of interest.
References
- 1.Adsay NV, Conlon KC, Zee SY, Brennan MF, Klimstra DS (2002) Intraductal papillary-mucinous neoplasms of the pancreas: an analysis of in situ and invasive carcinomas in 28 patients. Cancer 94:62–77PubMedCrossRefGoogle Scholar
- 2.Bloomston M, Zervos EE, Rosemurgy AS (2002) Matrix metalloproteinase and their role in pancreatic cancer: a review of preclinical studies and clinical trials. Ann Surg Oncol 9:668–674PubMedCrossRefGoogle Scholar
- 3.Folgueras AR, Pendás AM, Sánchez LM, López-Otín C (2004) Matrix metalloproteinase in cancers: from new functions to improved inhibition strategies. Int J Dev Biol 48:411–424PubMedCrossRefGoogle Scholar
- 4.Furukawa T, Kloppel G, Volkan Adsay N, Albores-Saavedra J, Fukushima N, Horii A, Hruban R, Kato Y, Klimstra DS, Longnecker DS, Luttges J, Offerhaus GJA, Shimizu M, Sunamura M, Suriawinata A, Takaori K, Yonezawa S (2005) Classification of types of intraductal papillary-mucinous neoplasm of the pancreas: a consensus study. Virchows Arch 447:794–799PubMedCrossRefGoogle Scholar
- 5.Harrel PC, McCawley LJ, Fingleton B, McIntyre O, Matrisian LM (2005) Proliferative effects of apical, but not basal, matrix metalloproteinase-7 activity in polarized MDCK cells. Exp Cell Res 303:308–320CrossRefGoogle Scholar
- 6.Ii M, Yamamoto H, Adachi Y, Maruyama Y, Shinomura Y (2006) Role of matrix metalloproteinase-7 (matrilysin) in human cancer invasion, apoptosis, growth, metalloproteinase and tissue inhibitor expression in pancreatic cancer: Increased expression of matrix metalloproteinase-7 predicts poor survival. Clin Cancer Res 10:2832–2845Google Scholar
- 7.Jones LE, Humphreys MJ, Campbell F, Neoptolemos JP, Boyd MT (2004) Comprehensive analysis of matrix metalloproteinase and tissue inhibitor expression in pancreatic cancer: increased expression of matrix metalloproteinase-7 predicts poor survival. Clin Cancer Res 10:2832–2845PubMedCrossRefGoogle Scholar
- 8.Leeman ML, Curan S, Murray GI (2003) New insights into the roles of matrix metalloproteinases in colorectal cancer development and progression. J Pathol 201:528–534PubMedCrossRefGoogle Scholar
- 9.Longnecker DS, Hruban RH, Adler G, Kloppel (2002) Intraductal papillary-mucinous neoplasms of the pancreas. In: Hamilton SR, Aaltonen LA (eds) Pathology and genetics of tumors of the digestive system (World Health Organization classification of tumours). IARC, Lyon, pp 237–240Google Scholar
- 10.Lynch CC, Matrisian LM (2002) Matrix metalloproteinases in tumor-host cell communication. Differentiation 70:561–573PubMedCrossRefGoogle Scholar
- 11.Lynch CC, Vargo-Gogola T, Martin MD, Fingleton B, Crawford HC, Matrisian LM (2007) Matrix metalloproteinase 7 mediates epithelial cell tumorigenesis through the ErbB4 receptor. Cancer Res 67:6760–6767PubMedCrossRefGoogle Scholar
- 12.Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM (2000) Matrix metalloproteinases: biological activity and clinical implications. J Clin Oncol 18:1135–1149PubMedGoogle Scholar
- 13.Parsa I, Longnecker DS, Scarpelli DG, Pour P, Reddy JK, Lefkowitz M (1985) Ductal metaplasia of human exocrine pancreas and its association with carcinoma. Cancer Res 45:1285–1290PubMedGoogle Scholar
- 14.Sasaki S, Yamamoto H, Kaneto H, Ozeki I, Adachi Y, Takagi H, Matsumoto T, Itoh H, Nagakawa T, Miyakawa H, Muraoka S, Fujinaga A, Suga T, Satoh M, Itoh F, Endo T, Imai K (2003) Differential roles of alterations of p53, p16, and SMAD4 expression in the progression of intraductal papillary-mucinous tumors of the pancreas. Oncol Rep 10:21–25PubMedGoogle Scholar
- 15.Sobin LH, Wittekind CH (eds) (2002) TNM clinical classification, pancreas. UICC TNM classification of malignant tumours, 6th edn. Wiley-Liss, New York, pp 93–96Google Scholar
- 16.Yamamoto H, Ito F, Iku S, Adachi Y, Fukushima H, Sasaki S, Mukaiya M, Hirata K, Imai K (2000) Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human pancreatic adenocarcinomas: clinicopathologic and prognostic significance of matrilysin expression. J Clin Oncol 19:1118–1127Google Scholar